Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of randomized trials

• Published in: Liver international Vol. 35; no. 8; pp. 2009 - 2016
• Main Authors: Thiele, Maja, Albillos, Agustín, Abazi, Rozeta, Wiest, Reiner, Gluud, Lise L., Krag, Aleksander
• Format: Journal Article
• Language: English
• Published: United States Blackwell Publishing Ltd 01.08.2015
• Subjects: Adrenergic beta-Antagonists - therapeutic use; Aged; beta-adrenergic antagonists; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - mortality; Carcinoma, Hepatocellular - prevention & control; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; hepatocellular carcinoma; Humans; liver cancer; Liver Cirrhosis - drug therapy; Liver Cirrhosis - pathology; Liver Neoplasms - drug therapy; Liver Neoplasms - mortality; Liver Neoplasms - prevention & control; Male; Middle Aged; Neovascularization, Pathologic - prevention & control; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome; beta-adrenergic antagonists; liver cancer; hepatocellular carcinoma
• ISSN: 1478-3223; 1478-3231
• DOI: 10.1111/liv.12782

Background & Aims Non‐selective beta‐blockers (NSBB) are used in patients with cirrhosis and oesophageal varices. Experimental data suggest that NSBB inhibit angiogenesis and reduce bacterial translocation, which may prevent hepatocellular carcinoma (HCC). We therefore assessed the effect of NSBB on HCC by performing a systematic review with meta‐analyses of randomized trials. Methods Electronic and manual searches were combined. Authors were contacted for unpublished data. Included trials assessed NSBB for patients with cirrhosis; the control group could receive any other intervention than NSBB. Fixed and random effects meta‐analyses were performed with I2 as a measure of heterogeneity. Subgroup, sensitivity, regression and sequential analyses were performed to evaluate heterogeneity, bias and the robustness of the results after adjusting for multiple testing. Results Twenty‐three randomized trials on 2618 patients with cirrhosis were included, of which 12 reported HCC incidence and 23 reported HCC mortality. The mean duration of follow‐up was 26 months (range 8–82). In total, 47 of 694 patients randomized to NSBB developed HCC vs 65 of 697 controls (risk difference −0.026; 95% CI−0.052 to −0.001; number needed to treat 38 patients). There was no heterogeneity (I2 = 7%) or evidence of small study effects (Eggers P = 0.402). The result was not confirmed in sequential analysis, which suggested that 3719 patients were needed to achieve the required information size. NSBB did not reduce HCC‐related mortality (RD −0.011; 95% CI −0.040 to 0.017). Conclusions Non‐selective beta‐blockers may prevent HCC in patients with cirrhosis.